174 related articles for article (PubMed ID: 30820752)
1. Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.
Lubowicka E; Zbucka-Kretowska M; Sidorkiewicz I; Zajkowska M; Gacuta E; Puchnarewicz A; Chrostek L; Szmitkowski M; Ławicki S
Pathol Oncol Res; 2020 Apr; 26(2):791-800. PubMed ID: 30820752
[TBL] [Abstract][Full Text] [Related]
2. Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Clin Lab; 2016 Sep; 62(9):1661-1669. PubMed ID: 28164586
[TBL] [Abstract][Full Text] [Related]
3. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
Sidorkiewicz I; Zbucka-Krętowska M; Zaręba K; Lubowicka E; Zajkowska M; Szmitkowski M; Gacuta E; Ławicki S
BMC Cancer; 2019 Apr; 19(1):398. PubMed ID: 31035945
[TBL] [Abstract][Full Text] [Related]
5. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Będkowska GE; Gacuta E; Szmitkowski M; Ławicki S
Cancer Control; 2018; 25(1):1073274818789357. PubMed ID: 30037277
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Gacuta E; Szmitkowski M; Chrostek L; Ławicki S
Tumour Biol; 2018 Jul; 40(7):1010428318790363. PubMed ID: 30052166
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Biomarkers; 2017 Mar; 22(2):157-164. PubMed ID: 27775427
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
[TBL] [Abstract][Full Text] [Related]
9. [The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients].
Lawicki S; Bedkowska E; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Pol Merkur Lekarski; 2008 Jul; 25(145):38-42. PubMed ID: 18839612
[TBL] [Abstract][Full Text] [Related]
10. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients.
Groblewska M; Mroczko B; Kozlowski M; Niklinski J; Laudanski J; Szmitkowski M
Folia Histochem Cytobiol; 2012; 50(4):590-8. PubMed ID: 23264224
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer.
Mroczko B; Lukaszewicz-Zając M; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2011; 49(1):125-31. PubMed ID: 21526499
[TBL] [Abstract][Full Text] [Related]
12. Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.
Sidorkiewicz I; Piskór B; Dąbrowska E; Guzińska-Ustymowicz K; Pryczynicz A; Zbucka-Krętowska M; Ławicki S
Anticancer Res; 2019 Nov; 39(11):6403-6412. PubMed ID: 31704874
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers.
Łukaszewicz-Zajac M; Mroczko B; Kozłowski M; Nikliński J; Laudański J; Szmitkowski M
Clin Chem Lab Med; 2010 Oct; 48(10):1467-73. PubMed ID: 20604722
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients.
Ławicki S; Będkowska GE; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Folia Histochem Cytobiol; 2012 Jul; 50(2):213-9. PubMed ID: 22763962
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients.
Łukaszewicz-Zając M; Mroczko B; Guzińska-Ustymowicz K; Pryczynicz A; Gryko M; Kemona A; Kędra B; Szmitkowski M
Adv Med Sci; 2013; 58(2):235-43. PubMed ID: 24384769
[TBL] [Abstract][Full Text] [Related]
16. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients.
Groblewska M; Mroczko B; Gryko M; Pryczynicz A; Guzińska-Ustymowicz K; Kędra B; Kemona A; Szmitkowski M
Tumour Biol; 2014 Apr; 35(4):3793-802. PubMed ID: 24395652
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients.
Groblewska M; Mroczko B; Wereszczyńska-Siemiatkowska U; Myśliwiec P; Kedra B; Szmitkowski M
Clin Chem Lab Med; 2007; 45(1):30-4. PubMed ID: 17243911
[TBL] [Abstract][Full Text] [Related]
18. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
19. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.
Walsh KM; Timms P; Campbell S; MacSween RN; Morris AJ
Dig Dis Sci; 1999 Mar; 44(3):624-30. PubMed ID: 10080160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
